Latest Hyperplasia Stories
SAN DIEGO, CA and VANCOUVER, BC, Nov. 6, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS), a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present an overview of the Company at the Lazard Capital Markets 9(th) Annual Healthcare Conference in New York. Mr. Woods' presentation will take place at 4:00 p.m. EST on Tuesday,...
SIPO of China has recently approved an alternative herbal treatment for endometrial hyperplasia and adenomyosis. Bringing no side effect, the herbal medicine completely treats endometrial disorders, which solves fertility problems for sufferers. Wuhan, Hubei Province (PRWEB) August 10, 2012 A new patented herbal medicine Fuyan Pill offers relief of two endometrial disorders: endometrial hyperplasia and adenomyosis, says Dr. Lee Xiaoping from Wuhan Dr. Lee's TCM Clinic. According to...
Spanish scientists have confirmed that there is a clear relationship between androgenetic alopecia (common premature baldness) and benign prostate hyperplasia (BPH), a benign enlargement of the prostate that appears in aging men and is associated with certain hormones as dihydrotestosterone. This condition appears in 50% of men over 60 year old and causes voiding syndrome i.e. urinary frequency. In the light of the study published in the journal of the American Academy of Dermatology, men...
SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of science-based solutions to oxidative stress, announced today that a new peer-reviewed study involving its flagship product, Protandim®, sponsored by the American Heart Association and the National Institutes of Health, was published in the scientific journal Free Radical Biology and Medicine. The study, conducted by researchers at The Ohio State University, examined the biochemical...
A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.The study, published online in Cardiovascular Research, reports that one of the scorpion's toxins, margatoxin, is at least 100 times more potent at preventing neointimal hyperplasia - the most comon cause of bypass graft failure - than any other known compound.Neointimal hyperplasia is the blood...
WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to longer than expected clinical development as well as competition from emerging novel injectable agents for the treatment of benign prostatic hyperplasia, Allergan's Botox will garner less market share than had been previously forecasted in the United States, France, Germany, Italy, Spain, the United Kingdom and...
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer."Postmenopausal hormone treatment is associated with increased rates of benign breast biopsies, and early and late stages of cancer. Atypical ductal hyperplasia is associated with the use of postmenopausal hormone treatment and its rates have decreased with the...
SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company will hold an Analyst Day on Thursday, September 24, 2009 beginning at 8:45 a.m. ET. A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...
An estimated 4 percent of older U.S. men suffer from dry eye, which can cause eye infections and bothersome symptoms, U.S. researchers said. Debra A. Schaumberg of Brigham and Women's Hospital and Harvard Medical School in Boston and colleagues estimated the prevalence of and examined risk factors for dry eye disease among 25,444 U.S. men who participated in the Physicians' Health Study I and II. Overall, 3 percent reported being diagnosed with dry eye, 6.8 percent experienced at least one...
SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)."...
